Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 4, 2005, Pages 371-378

  Kraemer, Richard ^a   Blum, Andrea ^a   Schibler, Andreas ^a   Ammann, Roland A ^a   Gallati, Sabina ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cystic fibrosis; Genotype; Onset of progression; Pseudomonas aeruginosa; Ventilation inhomogeneities

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ARTICLE; BODY PLETHYSMOGRAPHY; BREATH ANALYSIS; CHILD; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE COURSE; EVALUATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LUNG CLEARANCE; LUNG CLEARANCE INDEX; LUNG FLOW VOLUME CURVE; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG INFLATION; LUNG VENTILATION DISTRIBUTION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; PARAMETER; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEX DIFFERENCE; SPUTUM CULTURE; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; COHORT STUDIES; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG DISEASES; MALE; PLETHYSMOGRAPHY, WHOLE BODY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; PULMONARY VENTILATION; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEX FACTORS;

EID: 13544250572     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200407-948OC     Document Type: Article

References (72)

1. Wood R. Prognosis. In: Taussig LM, editor. Cystic fibrosis. New York: Thieme-Stratton; 1984. pp. 434-460.
2. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
3. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-1017.
4. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-1191.
5. Robinson W, Waltz DA. FEV(1) as a guide to lung transplant referral in young patients with cystic fibrosis. Pediatr Pulmonol 2000;30:198-202.
6. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-1313.
7. Lester LA, Kraut J, Lloyd-Still J, Karrison T, Mott C, Billstrand C, Lemke A, Ober C. Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics 1994;93:114-118.
8. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (delta F508). N Engl J Med 1990;323:1517-1522.
9. Johansen HK, Nir M, Hoiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 1991;337:631-634.
10. Liechti-Gallati S, Bonsall I, Malik N, Schneider V, Kraemer LG, Ruedeberg A, Moser H, Kraemer R. Genotype/phenotype association in cystic fibrosis: analyses of the delta F508, R553X, and 3905insT mutations. Pediatr Res 1992;32:175-178.
11. Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol 1996;22:387-395.
12. Aebi C, Bracher R, Liechti-Gallati S, Tschappeler H, Rudeberg A, Kraemer R. The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis-prognostic significance. Eur J Pediatr 1995;154:S69-S73.
13. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrell PM. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-287.
14. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
15. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Rock MJ, Splaingard ML. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 2003;168:1100-1108.
16. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-814.
17. Edwards LJ. Modern statistical techniques for the analysis of longitudinal data in biomedical research. Pediatr Pulmonol 2000;30:330-344.
18. Schibler A, Lüscher A, Ammann RA, Gallati S, Kraemer R. Progression of lung involvement in patients with cystic fibrosis (CF), assessed by longitudinal respiratory function measurements [abstract]. Eur Respir J 2002;20:20s.
19. Stern RC. The diagnosis of cystic fibrosis. N Engl J Med 1997;336:487-491.
20. Kraemer R, Birrer P, Liechti-Gallati S. Genotype-phenotype association in infants with cystic fibrosis at the time of diagnosis. Pediatr Res 1998;44:920-926.
21. Liechti-Gallati S, Schneider V, Neeser D, Kraemer R. Two buffer PAGE system-based SSCP/HD analysis: a general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease. Eur J Hum Genet 1999;7:590-598.
22. Bennett LC, Kraemer R, Liechti-Gallati S. Buccal cell DNA analysis in premature and term neonates: screening for mutations of the complete coding region for the cystic fibrosis transmembrane conductance regulator. Eur J Pediatr 2000;159:99-102.
23. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, Pantin C, Ali N, Shale DJ, Crane M. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000;55:355-358.
24. Schidlow DV, Taussig LM, Knowles MR. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993;15:187-198.
25. Consensus Conference Report. Use of aerosolized antibiotics in CF patients. Cystic Fibrosis Foundation (CFF). Bethesda, MD: 1997.
26. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767.
27. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
28. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004;17:57-71.
29. Kraemer R, Meister B. Fast real-time moment-ratio analysis of multibreath nitrogen washout in children. J Appl Physiol 1985;59:1137-1144.
30. Kraemer R, Zehnder M, Meister B. Intrapulmonary gas distribution in healthy children. Respir Physiol 1986;65:127-137.
31. Kraemer R, Schoui MH. Ventilatory inequalities, pulmonary function and blood oxygenation in advanced states of cystic fibrosis. Respiration 1990;57:318-324.
32. Newth CJ, Enright P, Johnson RL. Multiple-breath nitrogen washout techniques: including measurements with patients on ventilators. Eur Respir J 1997;10:2174-2185.
33. Hammer J, Numa A, Newth CJ. Total lung capacity by N2 washout from high and low lung volumes in ventilated infants and children. Am J Respir Crit Care Med 1998;158:526-531.
34. Morris MG. The open circuit nitrogen washout technique for measuring the lung volume in infants: methodological aspects. Thorax 1999;54:790-795.
35. Van Muylem A, Baran D. Overall and peripheral inhomogeneity of ventilation in patients with stable cystic fibrosis. Pediatr Pulmonol 2000;30:3-9.
36. Schibler A, Schneider M, Frey U, Kraemer R. Moment ratio analysis of multiple breath nitrogen washout in infants with lung disease. Eur Respir J 2000;15:1094-1101.
37. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003;22:972-979.
38. Aurora P, Bush A, Gustafsson P, Oliver C, Wallis C, Price J, Stroobant J, Carr S, Stocks J. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005;171:249-256.
39. Landau LI, Taussig LM, Macklem PT, Beaudry PH. Contribution of inhomogeneity of lung units to the maximal expiratory flow-volume curve in children with asthma and cystic fibrosis. Am Rev Respir Dis 1975;111:725-731.
40. Scherer PW, Neff JD, Baumgardner JE, Neufeld GR. The importance of a source term in modeling multibreath inert gas washout. Respir Physiol 1996;103:99-103.
41. Stromberg NO, Gustafsson PM. Ventilation inhomogeneity assessed by nitrogen washout and ventilation-perfusion mismatch by capnography in stable and induced airway obstruction. Pediatr Pulmonol 2000;29:94-102.
42. Manzke H, Stadlober E, Schellauf HP. Combined body plethysmographic, spirometric and flow volume reference values for male and female children aged 6 to 16 years obtained from "hospital normals. Eur J Pediatr 2001;160:300-306.
43. Dibley MJ, Goldsby JB, Staehling NW, Trowbridge FL. Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr 1987;46:736-748.
44. Zapletal A, Samanek M, Paul T. Lung function in children and adolescents. Basel, Switzerland: Karger; 1987.
45. Davis PB. The decline and fall of pulmonary function in cystic fibrosis: new models, new lessons. J Pediatr 1997;131:789-790.
46. Wang SS, O'Leary LA, Fitzsimmons SC, Khoury MJ. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002;141:804-810.
47. Rosenfeld M, Pepe MS, Longton G, Emerson J, FitzSimmons S, Morgan W. Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients. Pediatr Pulmonol 2001;31:227-237.
48. Tiddens HA. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 2002;34:228-231.
49. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003;36:230-240.
50. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 1994;124:177-192.
51. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
52. Dankert-Roelse JE, te Meerman GJ. Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre. Thorax 1995;50:712-718.
53. Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001;18:306-315.
54. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998;113:1230-1234.
55. Koscik RE, Kosorok MR, Farrell PM, Collins J, Peters ME, Laxova A, Green CG, Zeng L, Rusakow LS, Hardie RC, et al. Wisconsin cystic fibrosis chest radiograph scoring system: validation and standardization for application to longitudinal studies. Pediatr Pulmonol 2000;29:457-467.
56. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
57. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:1550-1555.
58. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, Marshall BC. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001;286:2683-2689.
59. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K, Wainwright C. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002;87:306-311.
60. Cystic Fibrosis Foundation. Data Report to the Center Directors. Cystic Fibrosis Foundation Patient Registry. Bethesda, MD; 2001.
61. Fry DL. Theoretical considerations of the bronchial pressure-flow-volume relationships with particular reference to the maximum expiratory flow volume curve. Phys Med Biol 1958;3:174-194.
62. Bouhuys A, Jonson B. Alveolar pressure, airflow rate, and lung inflation in man. J Appl Physiol 1967;22:1086-1100.
63. Hutchison AA, Sum AC, Demis TA, Erben A, Landau LI. Moment analysis of multiple breath nitrogen washout in children. Am Rev Respir Dis 1982;125:28-32.
64. Wall MA. Moment analysis of multibreath nitrogen washout in young children. J Appl Physiol 1985;59:274-279.
65. Habib RH, Lutchen KR. Moment analysis of a multibreath nitrogen washout based on an alveolar gas dilution number. Am Rev Respir Dis 1991;144:513-519.
66. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 67:117-133.
67. Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L. Predictors of deterioration of lung function in cystic fibrosLs. Pediatr Pulmonol 2002;33:483-491.
68. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116:714-719.
69. Wilmott RW, Tyson SL, Dinwiddie R, Matthew DJ. Survival rates in cystic fibrosis. Arch Dis Child 1983;58:835-836.
70. Grasemann H, Wiesemann HG, Ratjen F. The importance of lung function as a predictor of 2-year mortality in mucovisodosis. Pneumologie 1995;49:466-469.
71. Ratjen F, Comes G, Paul K, Posselt HG, Wagner TO, Harms K. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001;31:13-16.
72. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.